SCHEMBL5136696

SCHEMBL5136696

CCCCN(Cc1cc(C(=O)OCC)cc(C(=O)OCC)c1)Cc1cnc(-c2ccccc2)n1CCCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CNR2 P34972 2/20 0.39
PDE2A O00408 2/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
TSHR P16473 2/20 0.37
SIRT2 Q8IXJ6 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
GLA P06280 1/20 0.37
JMJD6 Q6NYC1 1/20 0.36
CYP19A1 P11511 1/20 0.36
MEP1B Q16820 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134921 0.94 NPC1 (0.40) NPC1RAB9ACNR2PDE2AALDH1A1
SCHEMBL5182726 0.87 SIRT2 (0.37) NPC1RAB9ACNR2PDE2AALDH1A1
SCHEMBL5135175 0.84 AGTR1 (0.43) RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL1912760 0.83 TSHR (0.48) ALDH1A1TSHR
SCHEMBL1912927 0.82 TSHR (0.39) NPC1TSHR
SCHEMBL5137530 0.81 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2LMNATSHRKMT2A
SCHEMBL5137532 0.81 TSHR (0.43) ALDH1A1MAPTTSHR
SCHEMBL5134681 0.80 KAT8 (0.41) TSHR
SCHEMBL5134636 0.79 AGTR1 (0.46) ALDH1A1MAPT
SCHEMBL5072278 0.78 TSHR (0.51) ALDH1A1SMN1; SMN2MAPK1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed